Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Sarcoma, Kaposi 1Oligodendroglioma 1Kidney Neoplasms 1Hematologic Neoplasms 1HIV Infections 1Gliosarcoma 1Glioma 1Glioblastoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1Acquired Immunodeficiency Syndrome 1

Interventions

pembrolizumab 47Nivolumab 34Sunitinib 18Cyclophosphamide 18Everolimus 17Ipilimumab 15cabozantinib 14pazopanib 13Bevacizumab 13fludarabine 12atezolizumab 11temsirolimus 10Magnetic Resonance Spectroscopy 10Sorafenib 9aldesleukin 8Specimen Handling 8Paclitaxel 8Sirolimus 7CTLA-4 Antigen 7Axitinib 7belzutifan 6Radiosurgery 6Oxaliplatin 6Interleukin-2 6Fluorouracil 6spartalizumab 5avelumab 5Leucovorin 5Irinotecan 5Docetaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Renal Cell × Muromonab-CD3 × Clear all
NCT00091611 2012-10-26

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
3 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡